Arvinas (ARVN) Soars 14% as Investors Cheer Pipeline Reset and Jefferies Update
Arvinas shares surged over 14% to the low-$13 range on November 18, 2025, with trading volume far above average. The move followed a pipeline reset, FDA acceptance of vepdegestrant’s New Drug Application, and cost-cutting plans including a 15% workforce reduction. The stock remains well below its 52-week high of $27.
